Image

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.

Description

PRIMARY OBJECTIVES:

I. To prospectively collect data on acute and late toxicities (including second malignant neoplasms) in patients treated with proton therapy.

II. To collect and store the corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.

SECONDARY OBJECTIVES:

I. To derive and refine dose-response relationships for normal tissue toxicity after proton therapy.

II. To document and compare symptom burden weekly during treatment and twice a month for 3 months after therapy, using the M.D. Anderson Symptom Inventory (MDASI).

OUTLINE

Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.

Eligibility

Inclusion Criteria:

  • All patients scheduled for radiation treatment with protons at UTMDACC are eligible for this protocol
  • Patients must sign a study-specific consent form prior to study entry

Exclusion Criteria:

  • Patients who are unable or unwilling to attend the required periodic follow-ups either at M.D. Anderson or at a different site

Study details
    Breast Carcinoma
    Esophageal Carcinoma
    Genitourinary System Carcinoma
    Head and Neck Carcinoma
    Hematopoietic and Lymphoid Cell Neoplasm
    Lung Carcinoma
    Malignant Central Nervous System Neoplasm
    Malignant Digestive System Neoplasm
    Malignant Solid Neoplasm

NCT00991094

M.D. Anderson Cancer Center

1 May 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.